Company intelligence / Profile preview

Telsar Pharma, Inc.

Bridgewater, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Telsar Pharma conducted a Phase 2, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ASP3291 in patients with active ulcerative colitis. The drug development was discontinued after this phase[2][7].

Therapeutic areas: Gastroenterology
Modalities: Small molecules (melanocortin receptor agonists)
Industry: Biotech

Drug pipeline

1 asset

ASP3291

Partnerships

Astellas Pharma Inc.Drais Pharmaceuticals, Inc.

Beyond the preview

Go deeper on Telsar Pharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Telsar Pharma, Inc..